April 16, 2012 — Medic Vision Imaging Solutions Ltd. announced that within six months of clinical use in the United States, its SafeCT image enhancement system has delivered diagnostic image quality to more than 20,000 CT (computed tomography) studies acquired with low-dose protocols.

April 16, 2012 - 480 Biomedical announced that it has initiated the first human trial of its groundbreaking Stanza self-expanding bioresorbable scaffold for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA). The Stanza scaffold restores blood flow to the leg by propping open the diseased artery during the critical healing period, similar to conventional metal stents, but then is resorbed by the body. Observations from the first patients in the STANCE trial were reported on April 14 at the 34th Charing
Cross International Symposium in London.

April 16, 2012 - Prime Healthcare Services (PHS), a hospital management company based in Ontario, Calif., currently owns and operates 16 acute-care hospitals. In February 2012, PHS signed a master agreement with Infinitt North America to replace PACS and cardiology PACS at several of its California hospitals.

April 15, 2012 - St. Jude Medical Inc., a global medical device company, announced CE Mark Approval of the Ellipse implantable cardioverter defibrillator (ICD). Designed with feedback from more than 200 physicians from around the world, the Ellipse ICD provides the benefits of advanced features and power in the industry’s smallest high-energy ICD.

April 16, 2012 — Philips Healthcare announced it is collaborating with Brainlab AG to create a comprehensive intra-operative magnetic resonance imaging (MRI) solution with the goal of streamlining neurosurgery procedures. Ingenia MR-OR is based on Philips’ digital broadband Ingenia MRI system, 1.5T and 3.0T, and is designed to be combined with Brainlab’s integrated operating room (OR) solutions.

April 13, 2012 — Researchers at The Ohio State University (OSU) Wexner Medical Center have successfully used nanotechnology to target a protein that plays a key role in atherosclerosis and inflammation, and say the study is an important advance toward using immunotherapy to simultaneously diagnose and treat cardiovascular disease.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now